Gefitinib kết hợp với Paclitaxel và Carboplatin trong điều trị ung thư phổi không tế bào nhỏ giai đoạn nặng: Thử nghiệm pha III—INTACT 2

Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 37:S4,2001–S66, (suppl 8)

10.1200/JCO.2001.19.13.3210

10.1056/NEJMoa011954

10.1016/S0163-7258(98)00045-X

10.1093/annonc/mdg250

10.1200/JCO.2002.10.112

10.1200/JCO.2002.03.038

10.1200/JCO.2002.03.100

10.1200/JCO.2003.10.038

Natale RB, Skarin A, Maddox A-M, et al: Improvement in symptoms and quality of life for advanced non–small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in IDEAL 2. Proc Am Soc Clin Oncol 21:292a,2002, (abstr 1167)

10.1001/jama.290.16.2149

10.1016/S0169-5002(02)00308-2

Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053,2000–2063,

Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885,2000–4892,

10.1200/JCO.2003.12.008

10.1200/JCO.2004.08.001

10.1001/jama.1997.03540350075038

10.1007/BF01218365

10.1002/sim.4780131509

10.1093/jnci/92.3.205

10.1091/mbc.4.1.121

Ravindranath N, Wion D, Brachet P, et al: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22:432,2001–443,

10.1067/mlc.2002.128317

Morikawa K, Walker SM, Nakajima M, et al: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863,1988–6871,

10.1016/S0140-6736(03)12190-3

10.1016/S0959-8049(01)00231-3

10.1634/theoncologist.7-suppl_4-31

Meye A, Fiedler U, Kunert K, et al: Growth inhibitory effects of ZD1839 (‘Iressa’) on human bladder cancer cell lines. Proc Am Assoc Cancer Res 42:805,2001, (abstr 4320)

Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184,2001–7188,

Janmaat ML, Kruyt FAE, Rodriquez JA, et al: Inhibition of the epidermal growth factor receptor induces apoptosis in A431 cells, but not in non-small-cell lung cancer cell lines. Proc Am Assoc Cancer Res 43:XX,2002, (abstr 3901)

Budillon A, Guarrasi R, Di Gennaro E, et al: ZD1839 (‘Iressa’), an EGFR tyrosine kinase inhibitor, potentiates non-Mhc restricted cytotoxicity in human cancer cell lines. Proc Am Assoc Cancer Res 42:XX,2001, (abstr 4306)

10.1056/NEJM200103153441101

Janas MS, Franklin WA, Schmidt K, et al: Interobserver reproducibility of visually interpreted EGFR immunohistochemical staining in non-small-cell lung cancer. Proc Am Assoc Cancer Res 44:XX,2003, (abstr LB-213)

Bailey LR, Kris M, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44:1362,2003, (abstr LB-170)